Ageless Forever Anti-Aging News Blog

Monica

Monica

Medical Writer & Nutritionist

MSc Nutrition

University of Stockholm & Karolinska Institute, Sweden 

   Baylor University, TX, USA

Website URL:

Efficacy and safety of injectable testosterone undecanoate (Aveed or Nebido) for the treatment of hypogonadism

Since its approval in 2004, many clinical studies have been conducted with testosterone undecanoate, the first long-acting injectable form of testosterone.
 
Testosterone undecanoate has been proven to have an excellent safety profile and need only be administered four times annually to produce stable testosterone levels.[1]
 
Long-term studies have validated the clinical efficacy of testosterone undecanoate in maintaining stable therapeutic levels of testosterone and safely conferring the desired benefits of androgen replacement.[1]
 
Here I summarize the results from a comprehensive meta-analysis of all uncontrolled and placebo-controlled randomized clinical trials (RCTs) demonstrating the effect of injectable testosterone undecanoate on multiple clinical outcomes.[2]
 

Testosterone Levels, Testosterone Therapy and Cardiovascular Risk in Men

Hypogonadism, also known as testosterone deficiency, is increasing in prevalence worldwide. While a rapidly expanding body of research is documenting the detrimental health consequences of hypogonadism, at the same time there is a prevailing concern and misunderstanding about the effects of testosterone therapy on cardiovascular risk.
 
In this article I present a summary of a recently published comprehensive review on the association of hypogonadism with cardiovascular risk factors, and the effect of testosterone therapy on those risk factors.[1]
 
Subscribe to this RSS feed

Dr. Pierce's Medical Organization Affiliations

  • 1-a4m.jpg
  • 2-ACAM.jpg
  • 3-AMMG.jpg
  • 4-American-Board-Anti-Aging-Regenerative-Medicine.jpg
  • 5-AAPMR.jpg
  • 6-acoep.jpg
  • 7-ISSM.jpg